vs
Bioceres Crop Solutions Corp.（BIOX）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
Repay Holdings Corp的季度营收约是Bioceres Crop Solutions Corp.的1.0倍（$78.6M vs $77.6M），Bioceres Crop Solutions Corp.净利率更高（-9.6% vs -178.3%，领先168.7%），Repay Holdings Corp同比增速更快（0.4% vs -16.8%），过去两年Repay Holdings Corp的营收复合增速更高（-1.3% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
BIOX vs RPAY — 直观对比
营收规模更大
RPAY
是对方的1.0倍
$77.6M
营收增速更快
RPAY
高出17.2%
-16.8%
净利率更高
BIOX
高出168.7%
-178.3%
两年增速更快
RPAY
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $78.6M |
| 净利润 | $-7.4M | $-140.1M |
| 毛利率 | 46.8% | 74.2% |
| 营业利润率 | 9.3% | -182.2% |
| 净利率 | -9.6% | -178.3% |
| 营收同比 | -16.8% | 0.4% |
| 净利润同比 | -20.2% | -3304.1% |
| 每股收益（稀释后） | $-0.12 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRPAY
| Q4 25 | — | $78.6M | ||
| Q3 25 | $77.6M | $77.7M | ||
| Q2 25 | — | $75.6M | ||
| Q1 25 | $60.6M | $77.3M | ||
| Q4 24 | $98.8M | $78.3M | ||
| Q3 24 | $93.3M | $79.1M | ||
| Q2 24 | — | $74.9M | ||
| Q1 24 | $84.0M | $80.7M |
净利润BIOXRPAY
| Q4 25 | — | $-140.1M | ||
| Q3 25 | $-7.4M | $-6.4M | ||
| Q2 25 | — | $-102.3M | ||
| Q1 25 | $-1.6M | $-7.9M | ||
| Q4 24 | $605.2K | $-4.1M | ||
| Q3 24 | $-6.2M | $3.2M | ||
| Q2 24 | — | $-4.1M | ||
| Q1 24 | $9.8M | $-5.2M |
毛利率BIOXRPAY
| Q4 25 | — | 74.2% | ||
| Q3 25 | 46.8% | 74.4% | ||
| Q2 25 | — | 75.7% | ||
| Q1 25 | 39.4% | 75.9% | ||
| Q4 24 | 42.0% | 76.3% | ||
| Q3 24 | 40.2% | 77.8% | ||
| Q2 24 | — | 78.2% | ||
| Q1 24 | 50.8% | 76.2% |
营业利润率BIOXRPAY
| Q4 25 | — | -182.2% | ||
| Q3 25 | 9.3% | -3.9% | ||
| Q2 25 | — | -138.7% | ||
| Q1 25 | 1.5% | -4.7% | ||
| Q4 24 | 14.5% | -1.5% | ||
| Q3 24 | 2.5% | -0.9% | ||
| Q2 24 | — | -4.6% | ||
| Q1 24 | 15.7% | -3.1% |
净利率BIOXRPAY
| Q4 25 | — | -178.3% | ||
| Q3 25 | -9.6% | -8.3% | ||
| Q2 25 | — | -135.2% | ||
| Q1 25 | -2.6% | -10.3% | ||
| Q4 24 | 0.6% | -5.3% | ||
| Q3 24 | -6.6% | 4.1% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | 11.6% | -6.5% |
每股收益（稀释后）BIOXRPAY
| Q4 25 | — | $-1.68 | ||
| Q3 25 | $-0.12 | $-0.08 | ||
| Q2 25 | — | $-1.15 | ||
| Q1 25 | $-0.02 | $-0.09 | ||
| Q4 24 | $0.00 | $-0.04 | ||
| Q3 24 | $-0.10 | $0.03 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | $0.14 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $115.7M |
| 总债务越低越好 | — | $280.1M |
| 股东权益账面价值 | $288.3M | $484.4M |
| 总资产 | $734.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资BIOXRPAY
| Q4 25 | — | $115.7M | ||
| Q3 25 | $15.5M | $95.7M | ||
| Q2 25 | — | $162.6M | ||
| Q1 25 | $38.5M | $165.5M | ||
| Q4 24 | $29.2M | $189.5M | ||
| Q3 24 | $32.3M | $168.7M | ||
| Q2 24 | — | $147.1M | ||
| Q1 24 | $16.4M | $128.3M |
总债务BIOXRPAY
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
股东权益BIOXRPAY
| Q4 25 | — | $484.4M | ||
| Q3 25 | $288.3M | $616.9M | ||
| Q2 25 | — | $633.7M | ||
| Q1 25 | $345.0M | $755.7M | ||
| Q4 24 | $346.3M | $761.3M | ||
| Q3 24 | $346.0M | $754.7M | ||
| Q2 24 | — | $815.4M | ||
| Q1 24 | $348.5M | $813.8M |
总资产BIOXRPAY
| Q4 25 | — | $1.2B | ||
| Q3 25 | $734.9M | $1.3B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | $798.2M | $1.5B | ||
| Q4 24 | $835.2M | $1.6B | ||
| Q3 24 | $827.3M | $1.6B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | $836.1M | $1.5B |
负债/权益比BIOXRPAY
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | — | $23.2M |
| 自由现金流率自由现金流/营收 | — | 29.6% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $90.7M |
8季度趋势，按日历期对齐
经营现金流BIOXRPAY
| Q4 25 | — | $23.3M | ||
| Q3 25 | $14.4M | $32.2M | ||
| Q2 25 | — | $33.1M | ||
| Q1 25 | $23.3M | $2.5M | ||
| Q4 24 | $-5.4M | $34.3M | ||
| Q3 24 | $5.2M | $60.1M | ||
| Q2 24 | — | $31.0M | ||
| Q1 24 | $-17.4M | $24.8M |
自由现金流BIOXRPAY
| Q4 25 | — | $23.2M | ||
| Q3 25 | — | $32.1M | ||
| Q2 25 | — | $33.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $34.0M | ||
| Q3 24 | — | $59.8M | ||
| Q2 24 | — | $30.5M | ||
| Q1 24 | — | $24.7M |
自由现金流率BIOXRPAY
| Q4 25 | — | 29.6% | ||
| Q3 25 | — | 41.3% | ||
| Q2 25 | — | 43.6% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 43.5% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 30.6% |
资本支出强度BIOXRPAY
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 0.1% |
现金转化率BIOXRPAY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -8.85× | — | ||
| Q3 24 | — | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOX
暂无分部数据
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
